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Background: Dyslipidemia is associated with increased heart failure (HF) risk. Lipid-modifying therapy is prescribed for primary prevention of 
coronary heart disease (CHD). Whether treatment-induced improvement in lipid profile in this setting is also associated with decreased HF risk is 
unclear.
methods: In 18,402 CHD-free Veteran males (mean age 68 years) receiving lipid-modifying therapy, we assessed the magnitude of treatment-
induced improvement (“delta [d]” = post-treatment value – pretreatment value) in high-density lipoprotein cholesterol (HDL-C), low density 
lipoprotein cholesterol (LDL-C) and triglycerides (TG). We related quintiles of d-HDL-C, d-LDL-C and d-TG to risk of incident HF, using multivariable-
adjusted Cox proportional hazards models.
results: Over a maximum follow-up period of 9 years, 911 HF events occurred. There was a graded decrease in HF risk across quintiles of 
increasing HDL-C improvement. Compared to patients in the first quintile, improvement in HDL-C was associated with up to 30% decrease in HF 
hazards (Table). Analyses adjusting for interim CHD events, or excluding participants developing interim CHD events showed similar Results. Delta-
LDL-C and delta-TG were not associated with any meaningful improvement in HF incidence.
conclusion: HDL-C improvement (but not LDL-C or TG lowering) was associated with decrease in incident HF. Our findings suggest HDL-C 
modification may have potential for primary prevention of HF in individuals free of CHD. 
Table: Relations of delta-HDL-C to incident HF 
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
No. of events/no. at risk (%) 167 / 3524 (4.7%) 192 / 4004 (4.8%) 163 / 3374 (4.8%) 189 / 3698 (5.1%) 200 / 3802 (5.3%)
Hazards ratio  (95% CI) Referent 0.77 (0.62, 0.95) 0.69 (0.55, 0.87) 0.67 (0.53, 0.83) 0.70 (0.56, 0.88)
CI = confidence interval; hazards ratios are adjusted for age, hypertension, diabetes, body mass index and baseline lipids.
